PROTECT: Panzyga for prevention of major infections in hypogammaglobulinemic patients on B-cell depletion therapy

Phase 3, randomised, double-blind trial in hypogammaglobulinemia, autoimmune disease, rheumatism and 13 more comparing Panzyga prophylaxis with Placebo (isotonic saline) (2 arms). Primary endpoint: Occurrence of at least one major infection or death. Planned start May 2026; status: authorised.